Department of Biochemistry, Weill Cornell Medicine, 1300 York Ave, New York, NY, 10065, USA.
Biochemistry, Cell and Molecular Biology Graduate Program, Weill Cornell Medicine, 1300 York Ave, New York, NY, 10065, USA.
Cell Commun Signal. 2023 Mar 13;21(1):58. doi: 10.1186/s12964-023-01084-6.
PD-L1, a transmembrane ligand for immune checkpoint receptor PD1, has been successfully targeted to activate an anti-tumor immune response in a variety of solid tumors, including non-small cell lung cancer (NSCLC). Despite the success of targeting PD-L1, only about 20% of patients achieve a durable response. The reasons for the heterogeneity in response are not understood, although some molecular subtypes (e.g., mutant EGF receptor tumors) are generally poor responders. Although PD-L1 is best characterized as a transmembrane PD1 ligand, the emerging view is that PD-L1 has functions independent of activating PD1 signaling. It is not known whether these cell-intrinsic functions of PD-L1 are shared among non-transformed and transformed cells, if they vary among cancer molecular subtypes, or if they are impacted by anti-PD-L1 therapy.
Here we use quantitative microscopy techniques and APEX2 proximity mapping to describe the behavior of PD-L1 and to identify PD-L1's proximal proteome in human lung epithelial cells.
Our data reveal growth factor control of PD-L1 recycling as a mechanism for acute and reversible regulation of PD-L1 density on the plasma membrane. In addition, we describe novel PD-L1 biology restricted to mutant EGFR cells. Anti-PD-L1 antibody treatment of mutant EGFR cells perturbs cell intrinsic PD-L1 functions, leading to reduced cell migration, increased half-life of EGFR and increased extracellular vesicle biogenesis, whereas anti-PD-L1 antibody does not induce these changes in wild type EGFR cells.
Growth factor acute regulation of PD-L1 trafficking, by contributing to the control of plasma membrane density, might contribute to the regulation of PD-L1's immune checkpoint activity, whereas the specific effects of anti-PD-L1 on mutant EGFR cells might contribute to the poor anti-PD-L1 response of mutant EGFR tumors. Video Abstract.
PD-L1 是免疫检查点受体 PD1 的跨膜配体,已成功靶向以激活多种实体瘤中的抗肿瘤免疫反应,包括非小细胞肺癌(NSCLC)。尽管靶向 PD-L1 取得了成功,但只有约 20%的患者获得持久反应。对于反应异质性的原因尚不清楚,尽管一些分子亚型(例如,突变型 EGFR 肿瘤)通常反应不佳。尽管 PD-L1 被认为是 PD1 信号激活的跨膜 PD-L1 配体,但新兴观点认为 PD-L1 具有独立于激活 PD1 信号的功能。尚不清楚这些 PD-L1 的细胞内功能是否在未转化和转化细胞中共享,如果它们在癌症分子亚型中存在差异,或者它们是否受到抗 PD-L1 治疗的影响。
本文使用定量显微镜技术和 APEX2 邻近作图来描述 PD-L1 的行为,并鉴定人肺上皮细胞中 PD-L1 的近端蛋白质组。
我们的数据揭示了生长因子对 PD-L1 回收的控制是急性和可逆调节 PD-L1 在质膜上密度的机制。此外,我们描述了仅限于突变型 EGFR 细胞的新型 PD-L1 生物学。抗 PD-L1 抗体治疗突变型 EGFR 细胞会扰乱细胞内 PD-L1 功能,导致细胞迁移减少、EGFR 半衰期增加和细胞外囊泡生物发生增加,而抗 PD-L1 抗体不会在野生型 EGFR 细胞中诱导这些变化。
生长因子对 PD-L1 转运的急性调节,通过控制质膜密度,可能有助于调节 PD-L1 的免疫检查点活性,而抗 PD-L1 对突变型 EGFR 细胞的特定影响可能导致突变型 EGFR 肿瘤对抗 PD-L1 反应不佳。视频摘要。